Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery

Here we report an ultra-long-acting tunable, biodegradable, and removable polymer-based delivery system that offers sustained drug delivery for up to one year for HIV treatment or prophylaxis. This robust formulation offers the ability to integrate multiple drugs in a single injection, which is particularly important to address the potential for drug resistance with monotherapy. Six antiretroviral drugs were selected based on their solubility in N-methyl-2-pyrrolidone and relevance as a combination therapy for HIV treatment or prevention. All drugs released with concentrations above their protein-adjusted inhibitory concentration and retained their physical and chemical properties within the formulation and upon release. The versatility of this formulation to integrate multiple drugs and provide sustained plasma concentrations from several weeks to up to one year, combined with its ability to be removed to terminate the treatment if necessary, makes it attractive as a drug delivery platform technology for a wide range of applications. Patient drug regime compliance is a major issue; sustained release implants could address this. Here, the authors report on a phase inverted in situ forming implant of PLGA for the sustained release of antiretroviral drugs and optimize and demonstrate the release of 6 different drugs over a period of up to a year.

[1]  G. Betageri,et al.  Effect of Co-Solvents on the Controlled Release of Calcitonin Polypeptide from In Situ Biodegradable Polymer Implants , 2005, Drug delivery.

[2]  Mohammad Erfan,et al.  Changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behavior. , 2009, Journal of pharmaceutical sciences.

[3]  H. Vinters,et al.  Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. , 1987, Science.

[4]  Chun-Wen Hsiao,et al.  An Implantable Depot That Can Generate Oxygen in Situ for Overcoming Hypoxia-Induced Resistance to Anticancer Drugs in Chemotherapy. , 2016, Journal of the American Chemical Society.

[5]  John D. Schreier,et al.  Correction to Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors. , 2016, Journal of Medicinal Chemistry.

[6]  I. Singh,et al.  Atrigel: A potential parenteral controlled drug delivery system , 2010 .

[7]  A. McHugh,et al.  Role of crystallization in the phase inversion dynamics and protein release kinetics of injectable drug delivery systems. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[8]  S. Pekamwar,et al.  High-Performance Liquid Chromatographic and High-Performance Thin-Layer Chromatographic Method for the Quantitative Estimation of Dolutegravir Sodium in Bulk Drug and Pharmaceutical Dosage Form , 2015, Scientia pharmaceutica.

[9]  Sabine Kempe,et al.  In situ forming implants - an attractive formulation principle for parenteral depot formulations. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[10]  R. Berges,et al.  Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer , 2006, Current medical research and opinion.

[11]  Tom O. McDonald,et al.  Dual-stimuli responsive injectable microgel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs. , 2017, Nanoscale.

[12]  A. McHugh,et al.  The role of polymer membrane formation in sustained release drug delivery systems. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[13]  K J Brodbeck,et al.  Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[14]  Christoph van Thriel,et al.  Quantitative risk analysis for N-methyl pyrrolidone using physiologically based pharmacokinetic and benchmark dose modeling. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[15]  Hamid Mobedi,et al.  Effect of additives on release profile of leuprolide acetate in an in situ forming controlled‐release system: In vitro study , 2008 .

[16]  Nureddin Ashammakhi,et al.  Temporal control of drug release from biodegradable polymer: multicomponent diclofenac sodium releasing PLGA 80/20 rod. , 2009, Journal of biomedical materials research. Part B, Applied biomaterials.

[17]  M. Fakhree,et al.  Review of pharmaceutical applications of N-methyl-2-pyrrolidone. , 2010, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[18]  I. Rupenthal,et al.  Injectable implants for the sustained release of protein and peptide drugs. , 2013, Drug discovery today.

[19]  David S Jones,et al.  Solvent induced phase inversion-based in situ forming controlled release drug delivery implants. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[20]  H. Ding,et al.  Generation of Transmitted/Founder HIV-1 Infectious Molecular Clones and Characterization of Their Replication Capacity in CD4 T Lymphocytes and Monocyte-Derived Macrophages , 2011, Journal of Virology.

[21]  Luis Solorio,et al.  The Effect of Additives on the Behavior of Phase Sensitive In Situ Forming Implants. , 2015, Journal of pharmaceutical sciences.

[22]  Luis Solorio,et al.  Effect of the Subcutaneous Environment on Phase-Sensitive In Situ-Forming Implant Drug Release, Degradation, and Microstructure. , 2015, Journal of pharmaceutical sciences.

[23]  W. Cui,et al.  Biomimetic Design of Mussel-Derived Bioactive Peptides for Dual-Functionalization of Titanium-Based Biomaterials. , 2016, Journal of the American Chemical Society.

[24]  John D. Schreier,et al.  Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors. , 2015, Journal of medicinal chemistry.

[25]  A. Perelson,et al.  Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection , 2009, The Journal of experimental medicine.

[26]  Luis Solorio,et al.  Noninvasive Characterization of the Effect of Varying PLGA Molecular Weight Blends on In Situ Forming Implant Behavior Using Ultrasound Imaging , 2012, Theranostics.

[27]  M. Boffito,et al.  A Validated Method for Quantification of Dolutegravir Using Ultra Performance Liquid Chromatography Coupled With UV Detection , 2016, Therapeutic drug monitoring.

[28]  A. Sambrone,et al.  Solvent-based formulations for intravenous mouse pharmacokinetic studies: tolerability and recommended solvent dose limits , 2014, Xenobiotica; the fate of foreign compounds in biological systems.

[29]  Hirenkumar K. Makadia,et al.  Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. , 2011, Polymers.

[30]  M. Rathbone,et al.  Long Acting Animal Health Drug Products: Fundamentals and Applications , 2013 .

[31]  Hui Xu,et al.  The Anti-Melanoma Efficiency of the Intratumoral Injection of Cucurbitacin-Loaded Sustained Release Carriers: In Situ-Forming Implants , 2015, AAPS PharmSciTech.

[32]  J. Leroux,et al.  N-methyl pyrrolidone/bone morphogenetic protein-2 double delivery with in situ forming implants. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[33]  D. Burgess,et al.  Long Acting Injections and Implants , 2012, Advances in Delivery Science and Technology.

[34]  B. Wynne,et al.  Relative Bioavailability of a Dolutegravir Dispersible Tablet and the Effects of Low‐ and High‐Mineral‐Content Water on the Tablet in Healthy Adults , 2017, Clinical pharmacology in drug development.

[35]  A. Klibanov,et al.  Dual functional polyelectrolyte multilayer coatings for implants: permanent microbicidal base with controlled release of therapeutic agents. , 2010, Journal of the American Chemical Society.

[36]  A. Boudier,et al.  PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[37]  G. Learn,et al.  Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis , 2013, Retrovirology.

[38]  M. Swanson,et al.  Human Breast Milk and Antiretrovirals Dramatically Reduce Oral HIV-1 Transmission in BLT Humanized Mice , 2012, PLoS pathogens.

[39]  Hongtao Xu,et al.  Identification of Novel Mutations Responsible for Resistance to MK-2048, a Second-Generation HIV-1 Integrase Inhibitor , 2010, Journal of Virology.

[40]  Trevor Coward,et al.  An In-Vitro Study , 2016 .

[41]  Jagdish Singh,et al.  Smart polymer based delivery systems for peptides and proteins. , 2007, Recent patents on drug delivery & formulation.

[42]  R. Desrosiers,et al.  Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission , 2015, PLoS pathogens.

[43]  R. Mumper,et al.  Ultra-long-acting removable drug delivery system for HIV treatment and prevention , 2018, Nature Communications.

[44]  J. Kost,et al.  Characterization of a polymeric PLGA-injectable implant delivery system for the controlled release of proteins. , 2000, Journal of biomedical materials research.

[45]  R. Zeldin,et al.  Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. , 2003, The Journal of antimicrobial chemotherapy.

[46]  A. Kashuba,et al.  Single and Multiple Dose Pharmacokinetics of Dolutegravir in the Genital Tract of HIV-Negative Women , 2013, Antiviral therapy.

[47]  Luis Solorio,et al.  Effect of cargo properties on in situ forming implant behavior determined by noninvasive ultrasound imaging , 2012, Drug Delivery and Translational Research.

[48]  O. Katare,et al.  In situ forming implant for controlled delivery of an anti-HIV fusion inhibitor. , 2012, International journal of pharmaceutics.

[49]  Luis Solorio,et al.  Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems. , 2010, Journal of biomedical materials research. Part A.

[50]  M. Wainberg,et al.  Dolutegravir Resistance Mutation R263K Cannot Coexist in Combination with Many Classical Integrase Inhibitor Resistance Substitutions , 2015, Journal of Virology.

[51]  P. D. Graham,et al.  Phase inversion dynamics of PLGA solutions related to drug delivery. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[52]  M. Wainberg,et al.  The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance , 2015, Journal of Virology.

[53]  Hui Li,et al.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.